Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial

[1]  A. Zietman,et al.  Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. , 2017, European urology.

[2]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[3]  A. Ravaud,et al.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. , 2015, The Lancet. Oncology.

[4]  V. Valentini,et al.  Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial , 2014, BioMed research international.

[5]  J. Debus,et al.  Helical intensity-modulated Radiotherapy of the Pelvic Lymph Nodes with Integrated Boost to the Prostate Bed - Initial Results of the PLATIN 3 Trial , 2014, BMC Cancer.

[6]  T. Nemoto,et al.  Remodeling of the pulmonary artery induced by metastatic gastric carcinoma: a histopathological analysis of 51 autopsy cases , 2014, BMC Cancer.

[7]  S. Goldenberg,et al.  Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. , 2013, The Journal of urology.

[8]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[10]  I. Palumbo,et al.  Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma. , 2012, International journal of radiation oncology, biology, physics.

[11]  F. Montorsi,et al.  High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. , 2012, International journal of radiation oncology, biology, physics.

[12]  F Levi,et al.  European cancer mortality predictions for the year 2012. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  B. Hickey,et al.  Adjuvant radiotherapy following radical prostatectomy for prostate cancer. , 2011, The Cochrane database of systematic reviews.

[14]  M. Marberger,et al.  Quantification of extraprostatic perineural spread and its prognostic value in pT3a pN0 M0 R0 prostate cancer patients , 2011, The Prostate.

[15]  A. Hoznek,et al.  Impact of positive surgical margins on prostate‐specific antigen failure after radical prostatectomy in adjuvant treatment‐naïve patients , 2011, BJU international.

[16]  M. Roach,et al.  Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. , 2011, International journal of radiation oncology, biology, physics.

[17]  U. Capitanio,et al.  Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. , 2011, European urology.

[18]  A. Kibel.  Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95 , 2010 .

[19]  Henry Z. Montes,et al.  TNM Classification of Malignant Tumors, 7th edition , 2010 .

[20]  F. Montorsi,et al.  Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. , 2009, International journal of radiation oncology, biology, physics.

[21]  N. Willich,et al.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Hancock,et al.  Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. , 2007, International journal of radiation oncology, biology, physics.

[23]  E. Messing,et al.  Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. , 2006, JAMA.

[24]  T. Wiegel,et al.  Vermeidung des Lokalrezidivs durch eine adjuvante Strahlentherapie nach radikaler Prostatektomie , 2006, Der Urologe.

[25]  M. Zelefsky.  Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) , 2006 .

[26]  M. Piérart,et al.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.

[27]  K. Harada,et al.  Long‐term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer , 2004, International journal of urology : official journal of the Japanese Urological Association.

[28]  B. Corn,et al.  Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. , 1999, Urology.

[29]  B W Corn,et al.  Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. , 1998, International journal of radiation oncology, biology, physics.

[30]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[31]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[32]  E. Bocian,et al.  The mechanism of action of cis-dichloro-bis (isopropylamine) trans dihydroxyplatinum IV (CHIP) on Chinese hamster and C3H mouse tumor cells and its interaction with X-irradiation. , 1979, International journal of radiation oncology, biology, physics.

[33]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[35]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[36]  M. Anscher,et al.  Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy , 2013, Cancer.

[37]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[38]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[39]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.